Google is enacting a new data deletion policy for Android apps that allow account creation to also offer users with a setting to delete their accounts in an attempt to provide more transparency and control over their data.
“For apps that enable app account creation, developers will soon need to provide an option to initiate account and data deletion from within the app and online,” Bethel Otuteye, senior director of product management for Android App Safety, said.
“This web requirement, which you will link in your Data safety form, is especially important so that a user can request account and data deletion without having to reinstall an app.”
Writing a report on the state of AI must feel a lot like building on shifting sands: By the time you hit publish, the whole industry has changed under your feet. But there are still important trends and takeaways in Stanford’s 386-page bid to summarize this complex and fast-moving domain.
The AI Index, from the Institute for Human-Centered Artificial Intelligence, worked with experts from academia and private industry to collect information and predictions on the matter. As a yearly effort (and by the size of it, you can bet they’re already hard at work laying out the next one), this may not be the freshest take on AI, but these periodic broad surveys are important to keep one’s finger on the pulse of industry.
This year’s report includes “new analysis on foundation models, including their geopolitics and training costs, the environmental impact of AI systems, K-12 AI education, and public opinion trends in AI,” plus a look at policy in a hundred new countries.
There are approximately 30 trillion cells in a human body and our health is predicated on them properly interacting with and supporting each other, with the immune system playing a particularly pivotal role. One of the defining characteristics of aging is a decline in the proper functioning of our immune system. Centenarians, a rare population of individuals who reach 100 years or more, experience delays in aging-related diseases and mortality which suggests their immune systems remain functional into extreme old age.
Led by researchers from Boston University Chobanian & Avedisian School of Medicine and Tufts Medical Center, a new study finds centenarians harbor distinct immune cell type composition and activity and possess highly functional immune systems that have successfully adapted to a history of sickness allowing for exceptional longevity. These immune cells may help identify important mechanisms to recover from disease and promote longevity.
“Our data support the hypothesis that centenarians have protective factors that enable to recover from disease and reach extreme old ages,” said lead author Tanya Karagiannis, Ph.D., senior bioinformatician, Center for Quantitative Methods and Data Science, Institute for Clinical Research and Health Policy Studies at Tufts Medical Center.
Anti AI / AI ethics clowns now pushing.gov for some criminalization, on cue.
A nonprofit AI research group wants the Federal Trade Commission to investigate OpenAI, Inc. and halt releases of GPT-4.
OpenAI “has released a product GPT-4 for the consumer market that is biased, deceptive, and a risk to privacy and public safety. The outputs cannot be proven or replicated. No independent assessment was undertaken prior to deployment,” said a complaint to the FTC submitted today by the Center for Artificial Intelligence and Digital Policy (CAIDP).
Calling for “independent oversight and evaluation of commercial AI products offered in the United States,” CAIDP asked the FTC to “open an investigation into OpenAI, enjoin further commercial releases of GPT-4, and ensure the establishment of necessary guardrails to protect consumers, businesses, and the commercial marketplace.”
Reliable carbon-free power for the world — michelle catts, senior vice president, nuclear programs, ge-hitachi nuclear energy.
Michelle Catts is the Senior Vice President of Nuclear Programs at GE-Hitachi (GEH — https://nuclear.gepower.com/) located in Wilmington, NC.
Ms. Catts has over 18 years of demonstrated managerial and technical expertise in nuclear Regulatory Affairs and currently is responsible for ensuring world-class Quality, Continuous Improvement, Regulatory Affairs, and oversight of Environment, Health & Safety programs. She manages a multimillion-dollar budget and over a 30-member organization. She provides licensing and quality leadership and guidance to support nuclear fuel facility licensing, current nuclear fleet fuel reload/outage licensing activities, new reactor and new fuel opportunities, Technical Regulations and Standards, and GE-Hitachis’s Vallecitos and Morris sites.
Prior to joining GE-Hitachi, Ms. Catts worked for the U.S. Nuclear Regulatory Commission (NRC) where she held positions of increasing responsibility including as a nuclear reactor inspector stationed onsite at nuclear power plants up to the Policy Advisor to the Presidential Appointed NRC Chairman.
Ms. Catts holds a B.S. in Nuclear Engineering from North Carolina State University and is currently working on her MBA at UNCW.
Regeneration, Resuscitation & Biothreat Countermeasures — Commander Dr. Jean-Paul Chretien, MD, Ph.D., Program Manager, Biological Technology Office, DARPA
Commander Dr. Jean-Paul Chretien, MD, Ph.D. (https://www.darpa.mil/staff/cdr-jean-paul-chretien) is a Program Manager in the Biological Technology Office at DARPA, where his research interests include disease and injury prevention, operational medicine, and biothreat countermeasures. He is also responsible for running the DARPA Triage Challenge (https://triagechallenge.darpa.mil/).
Prior to coming to DARPA, CDR Dr. Chretien led the Pandemic Warning Team at the Defense Intelligence Agency’s National Center for Medical Intelligence, and as a naval medical officer, his previous assignments include senior policy advisor for biodefense in the White House Office of Science and Technology Policy; team lead for Innovation & Evaluation at the Armed Forces Health Surveillance Branch; and director of force health protection for U.S. and NATO forces in southwestern Afghanistan.
A proud mentor to nine graduate students and Oak Ridge Institute for Science and Education (ORISE) fellows, CDR Dr. Chretien received the Rising Star Award from the American College of Preventive Medicine, Best Publication of the Year Award from the International Society for Disease Surveillance, and Skelton Award for Public Service from the Harry S. Truman Scholarship Foundation. He has published over 50 peer-reviewed journal articles and 10 book chapters.
CDR Dr. Chretien earned a Bachelor of Science degree in political science from the United States Naval Academy, Master of Health Science in biostatistics and Doctor of Philosophy in genetic epidemiology degrees from the Johns Hopkins Bloomberg School of Public Health, and a Doctor of Medicine degree from the Johns Hopkins University School of Medicine. He completed his residency in general preventive medicine at the Walter Reed Army Institute of Research and fellowship in health sciences informatics at the Johns Hopkins University School of Medicine.
Dedicated to ending the HIV epidemic — dr. moupali das, MD, MPH, executive director, HIV clinical research, gilead sciences.
Dr. Moupali Das, MD, MPH, is Executive Director, HIV Clinical Research, in the Virology Therapeutic Area, at Gilead Sciences (https://www.gilead.com/), where she leads the pre-exposure prophylaxis (PrEP) clinical drug development program, including evaluating the safety and efficacy of a long-acting, twice yearly, subcutaneous injection being studied for HIV prevention. Her responsibilities also include expanding the populations who may benefit from PrEP.
Dr. Das has led high-performing teams in academic medicine, public health, implementation science, and cross-functionally in drug development. She has successfully helped develop, implement, and evaluate how to better test, link to care, increase virologic suppression, and improve quality of life for people with HIV, and to prevent HIV in those who may benefit from PrEP.
During the COVID19 pandemic, Dr. Das assisted her colleagues in the COVID-19 treatment program, leading the evaluation of a COVID-19 treatment for use in pregnant women and children from the compassionate use program.
After completing her undergraduate degree in Biochemical Sciences at Harvard College, medical school and internal medicine residency training at Columbia University and New York Presbyterian Hospital, Dr. Das came to University of California, San Francisco (UCSF) for fellowship training in Infectious Diseases and to University of California, Berkeley for her MPH in Epidemiology. She cared for HIV patients at San Francisco General’s storied Ward 86 clinic and attended on the inpatient ID Consult Service. She is recognized internally and externally for her expertise in epidemiology, public health, advocacy, and community engagement.
Blake Lemoine, the Google engineer fired for violating the company’s confidentiality policy, has now expressed concerns about the risks associated with AI-driven chatbots like Microsoft’s Bing AI.
The latest AI models, according to him, are the most potent technological advancement since the atomic bomb and can alter the course of history fundamentally.
As the ChatGPT and Whisper APIs launch this morning, OpenAI is changing the terms of its API developer policy, aiming to address developer — and user — criticism.
Starting today, OpenAI says that it won’t use any data submitted through its API for “service improvements,” including AI model training, unless a customer or organization opts in. In addition, the company is implementing a 30-day data retention policy for API users with options for stricter retention “depending on user needs,” and simplifying its terms and data ownership to make it clear that users own the input and output of the models.
Greg Brockman, the president and chairman of OpenAI, asserts that some of these changes aren’t changes necessarily — it’s always been the case that OpenAI API users own input and output data, whether text, images or otherwise. But the emerging legal challenges around generative AI and customer feedback prompted a rewriting of the terms of service, he says.
Advancing Biomedical R&D & Clinical Development In Saudi Arabia — Dr. Abdelali Haoudi, Ph.D., Managing Director, Biotechnology Park, King Abdullah International Medical Research Center, Ministry of National Guard Health Affairs.
Dr. Abdelali Haoudi, Ph.D. (https://kaimrc-biotech.org.sa/dr-abdelali-haoudi/) currently leads Strategy and Business Development functions, and is also Managing Director of the Biotechnology Park, at King Abdullah International Medical Research Center, at the Ministry of National Guard Health Affairs. He is also Distinguished Scholar at Harvard University-Boston Children’s Hospital.
Dr. Haoudi is an international Research & Development and Innovation Executive with over 25 years experience, having held several senior positions in Research and Development and Innovation. He has vast experience in science and technology policy development, strategy and business development, corporate development and international partnerships development.
Dr. Haoudi has held several senior and prestigious positions in the academia, government and private sectors globally, including North America, North Africa, Europe and Middle East. Some of the key positions include Founding Vice President for Research, Executive Director for Biomedical Research Institute, and Chairman, at the National Research Fund at Qatar Foundation.
Dr. Haoudi was also Research Professor of cancer and infectious diseases at the University of Virginia and Eastern Virginia Medical School and a fellow of the US National Institutes of Health (NIH). He has held several other positions in elite research and education institutions including Visiting Professor at Harvard Medical School (USA) and a fellow at Institute Pasteur (France).
